Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Amylyx Pharmaceuticals Inc AMLX

Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:AMLX)

Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire June 4, 2024

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. (NASDAQ: SAVA), iRhythm Technologies, Inc. (NASDAQ: IRTC), Xponential Fitness, Inc. (NYSE: XPOF), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Accesswire May 31, 2024

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Business Wire May 9, 2024

Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference

Business Wire May 8, 2024

Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

Business Wire May 2, 2024

Lifshitz Law PLLC Announces Investigations of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX), Cassava Sciences, Inc. (NASDAQ:SAVA), GrafTech International Ltd. (NYSE:EAF), and Mobileye Global Inc. (NASDAQ:MBLY)

Accesswire April 25, 2024

Lifshitz Law PLLC Announces Investigations of Meta Platforms, Inc. (NASDAQ: META), Amplitude, Inc. (NASDAQ: AMPL), ON Semiconductor Corporation (NASDAQ: ON), and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)

Accesswire April 16, 2024

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

Business Wire April 10, 2024

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Newsfile April 9, 2024

Opinion & Analysis (NDAQ:AMLX)

No current opinion is available.

Bullboard Posts (NDAQ:AMLX)

CAN AMX0035 BE A POTENTIAL GAME CHANGER IN ALS?

  $AMLX   Excited to share an article about Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) that is awaiting regulatory...
AviseAnalytics - March 16, 2022